Relmada to present positive 12-month Phase 2 data for NDV-01 in bladder cancer at AUA2026

Relmada Therapeutics announced it will present updated 12-month Phase 2 data for NDV-01, a sustained-release bladder cancer treatment, at the American Urology Association meeting in May 2026. The data show a 95% complete response rate at any time and a durable 76% response at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC). Relmada also plans to share an overview of its Phase 3 RESCUE trial, which is on track to start mid-2026. This progress highlights NDV-01's potential as a convenient, effective therapy for a bladder cancer subtype with limited options.